Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Bre...(nd whether a screening ultrasound exam s...),Health

Date:5/13/2008

nd whether a screening ultrasound exam supplemental to mammography might be beneficial, keeping in mind the potential for a false positive result and an unnecessary biopsy. At present, there is a limited supply of trained personnel and facilities who offer screening ultrasound. Women also should consult their health insurance policy regarding the coverage for breast cancer screening options. An annual mammogram is still recommended: neither MRI nor ultrasound is meant to replace mammography.

The study continues to follow participants to examine the potential benefit of routine annual combination screening of mammography and ultrasound.

For a listing of participating sites, please visit:

http://www.acrin.org/PROTOCOLSUMMARYTABLE/PROTOCOL6666/6666PARTICIPATIN GSITES/tabid/169/Default.aspx

Today, there are more than 33,000 radiologists practicing in the United States. As the medical doctors who specialize in diagnosing and treating disease and injury through medical imaging, radiologists are the experts in imaging care. Most radiologists have completed at least 13 years of training, including medical school, licensing, a four-year residency, and often a one- to two-year fellowship of specialized training.

'/>"/>

SOURCE American College of Radiology Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
7. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
8. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research